• Dana Incorporated recently entered into its Eighth Amendment to the 2016 Credit and Guaranty Agreement, adding a new US$500.0 million senior secured delayed draw term loan A facility that can be drawn once before August 1, 2026 and matures 364 days after borrowing.
• Dana plans to draw this facility in full to redeem all outstanding 8.500% Senior Notes due 2031 at a 104.250% redemption price, signaling an active reshaping of its debt mix and near‑term liquidity profile through secured bank financing.
• We’ll now examine how replacing the 2031 high‑coupon notes with this secured term loan could influence Dana’s investment narrative and risk profile.

Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

Dana Investment Narrative Recap

To own Dana, you need to believe it can turn its concentrated light‑vehicle and North American exposure into steadier earnings while executing on cost and margin plans. The new US$500.0 million secured term loan used to redeem the 8.500% 2031 notes reshapes near term funding, but does not materially change the core near term catalyst around execution or the key risk from end market cyclicality and customer concentration.

The most relevant recent announcement here is Dana’s January 2026 debt tender, funded with proceeds from the off‑highway business sale. That earlier move reduced and reshaped parts of the bond stack, and the new delayed draw term loan continues this pattern of refinancing activity. Together, they frame the near term catalyst around how effectively Dana manages leverage, interest expense and liquidity while still funding program launches and cost initiatives.

But while this refinancing may help with near term flexibility, investors should also be aware that...

Dana's narrative projects $11.5 billion revenue and $1.1 billion earnings by 2029.

Uncover how Dana's forecasts yield a $39.43 fair value, a 45% upside to its current price.

Exploring Other Perspectives

The lowest analysts were already cautious, assuming revenue of about US$12.2 billion and earnings of US$1.1 billion by 2029, and they worry that heavy reliance on backlog ramping late in the decade could collide with the new short dated secured debt in ways that shift the risk balance further.

Explore 2 other fair value estimates on Dana - why the stock might be worth just $39.43!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Dana research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Dana research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Dana's overall financial health at a glance.

Interested In Other Possibilities?

Our top stock finds are flying under the radar-for now. Get in early:

• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 46 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.